口服普萘洛尔治疗婴幼儿头面部血管瘤的临床研究

Clinical study of oral propranolol in the treatment of infantile cephalofacial hemangioma

目的探讨口服普萘洛尔治疗婴幼儿头面部血管瘤的临床疗效及安全性。方法选择我院皮肤科2019年5月至2020年5月收治的50例头面部血管瘤婴幼儿作为研究对象,根据随机数字表法将其分为A组(n=25)和B组(n=25),其中A组患儿口服普萘洛尔1 mg/(kg·d),B组患儿口服普萘洛尔2 mg/(kg·d),疗程6个月或满足停药标准后停药,采用Achauer 4级评分法评估两组治疗效果,比较两组治疗期间不良反应发生情况,比较两组停药时间、瘤体厚度。结果B组患儿治疗总有效率高于A组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。B组患儿治疗持续时间短于A组,差异有统计学意义(P<0.05)。B组治疗后瘤体最大厚度低于A组,差异有统计学意义(P<0.05)。结论剂量为2 mg/(kg·d)的普萘洛尔治疗婴幼儿头面部血管瘤能够提高治疗效果,缩短治疗时间,用药安全性高。

Objective To explore the clinical efficacy and safety of oral propranolol in the treatment of infantile hemangioma on head and face.Methods A total of 50 infants with head and face hemangioma treated in the Dermatology Department of our hospital from May 2019 to May 2020 were selected as the research objects,and they were divided into group A(n=25)and group B(n=25)according to the random number table method.The patients in group A were given propranolol at 1 mg/(kg·d)orally,while those in group B were given propranolol orally at 2 mg/(kg·d).The treatment was stopped after 6 months of treatment or after meeting the criteria of drug withdrawal.The therapeutic effects of the two groups were evaluated by Achauer′s grade scale.The adverse reactions of the two groups during treatment were compared,and the time of drug withdrawal and the thickness of the tumor were compared between the two groups.Results The total effective rate of group B was higher than that of group A,and the difference was statistically significant(P<0.05).The incidence of adverse reactions was 16.00%in group A and 20.00%in group B,with no significant difference between the two groups(P>0.05).The treatment time in group B was shorter than that in group A,with statistically significant difference(P<0.05).After treatment,the maximum thickness of tumor in group B was smaller than that in group A,with statistically significant difference(P<0.05).Conclusion Propranolol at a dose of 2 mg/(kg·d)can improve the treatment effect,shorten the treatment time and have high medication safety in the treatment of infantile hemangioma on head and face.